- Home
- FONR vs IFRX Comparison
FONR vs IFRX Comparison
Compare FONR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FONR
- IFRX
- Stock Information
- Founded
- FONR 1978
- IFRX 2007
- Country
- FONR United States
- IFRX Germany
- Employees
- FONR N/A
- IFRX N/A
- Industry
- FONR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- FONR Health Care
- IFRX Health Care
- Exchange
- FONR Nasdaq
- IFRX Nasdaq
- Market Cap
- FONR 77.1M
- IFRX 65.8M
- IPO Year
- FONR 1987
- IFRX 2017
- Fundamental
- Price
- FONR $14.41
- IFRX $0.81
- Analyst Decision
- FONR
- IFRX Strong Buy
- Analyst Count
- FONR 0
- IFRX 4
- Target Price
- FONR N/A
- IFRX $7.75
- AVG Volume (30 Days)
- FONR 42.9K
- IFRX 730.3K
- Earning Date
- FONR 05-15-2025
- IFRX 05-07-2025
- Dividend Yield
- FONR N/A
- IFRX N/A
- EPS Growth
- FONR N/A
- IFRX N/A
- EPS
- FONR 1.28
- IFRX N/A
- Revenue
- FONR $103,018,089.00
- IFRX $140,242.00
- Revenue This Year
- FONR N/A
- IFRX $3.36
- Revenue Next Year
- FONR N/A
- IFRX $100.60
- P/E Ratio
- FONR $11.36
- IFRX N/A
- Revenue Growth
- FONR 0.29
- IFRX 30.90
- 52 Week Low
- FONR $12.00
- IFRX $0.71
- 52 Week High
- FONR $18.68
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- FONR 67.86
- IFRX 32.16
- Support Level
- FONR $14.20
- IFRX $0.71
- Resistance Level
- FONR $14.59
- IFRX $0.89
- Average True Range (ATR)
- FONR 0.55
- IFRX 0.13
- MACD
- FONR 0.16
- IFRX -0.13
- Stochastic Oscillator
- FONR 96.17
- IFRX 7.39
About FONR Fonar Corporation
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.